Profiling of mRNA expression in quadriceps of patients with COPD and muscle wasting

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 2, 2008, Pages 75-84

  Debigaré, Richard ^a   Maltais, François ^a   Côté, Claude H ^b   Michaud, Annie ^a   Caron, Marc André ^a   Mofarrahi, Mahroo ^c   LeBlanc, Pierre ^a   Hussain, Sabah N A ^c  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Forkhead box O; Insulin growth factor 1; mRNA expression; N methyltransferase; Quadriceps muscle

Indexed keywords

AUTACOID; CARRIER PROTEIN; CYTOSKELETON PROTEIN; MESSENGER RNA; MUSCLE PROTEIN; NICOTINAMIDE METHYLTRANSFERASE; PROTEIN; PROTEINASE INHIBITOR; SCLEROPROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1;

AGED; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOWN REGULATION; ENERGY YIELD; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MALE; MUSCLE ATROPHY; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; TOTAL LUNG CAPACITY; UPREGULATION;

AGED; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MUSCULAR ATROPHY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUADRICEPS MUSCLE; RNA, MESSENGER; VITAL CAPACITY;

EID: 42249083542     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550801940457     Document Type: Article

References (59)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280.
2. Berchtold MW, Brinkmeier H, Muntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 2000; 80:1215-1265.
3. Gosselink R, Troosters T, Decramer M. Peripheralmuscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996, 153:976-980.
4. Mostert R, Goris A, Weling-Scheepers C, Wouters EFM, Schols AMW. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94:859-867.
5. Marquis K, Debigare R, Lacasse Y, Leblanc P, Jobin J, Carrier G, Maltais F. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:809-813.
6. Bernard S, Whittom F, Leblanc P, Jobin J, Belleau R, Bérubé C, Carrier G, Maltais F. Aerobic and strength training in patients with COPD. Am J Respir Crit Care Med 1999; 159:896-901.
7. Schols AMWJ, Soeters PB, Mostert R, Pluymers RJ, Wouters EFM. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152:1268-1274.
8. Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Brooks D, Jardim JR. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28.
9. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-1773.
10. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5:87-90.
11. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4:183-190.
12. Mitch WE, Goldberg AL. Mechanism of muscle wasting. N Engl J Med 1996; 335:1897-1905.
13. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
14. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98:14440-14445.
15. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19:362-370.
16. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett 2002; 180:69-74.
17. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003; 285:C806-C812.
18. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
19. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. Embo J 1996; 15:1753-1765.
20. Langen RC, Schols AM, Kelders MC, Van Der Velden JL, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and - independent pathways. Am J Physiol Cell Physiol 2002; 283:C714-C721.
21. Rennie MJ, Wackerhage H, Spangenburg EE, Booth FW. Control of the size of the human muscle mass. Annu Rev Physiol 2004; 66:799-828.
22. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120.
23. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability and effects of age. Am Rev Respir Dis 1976; 113:587-600.
24. Goldman HI, Becklake MR. Respiratory function tests: normal values at median altitudes and the prediction of normal results. Am Rev Tuberc 1959; 79:454-467.
25. Heymsfield SB, Williams PJ. Nutritional assessment by clinical and biochemical methods. In Modern nutrition in health and disease. Edited by Shils ME, Olson JA. Philadelphia: Lea & Febiger; 1994:812-841.
26. Bergström J. Muscle electrolytes in man. Determination by neutron activation analysis on needle biopsy specimens. A study on normal subjects, kidney patients and patients with chronic diarrhoea. Scand J Clin and Lab Invest 1962; 14:1-110.
27. Novak JP, Sladek R, Hudson TJ. Characterization of variability in large-scale gene expression data: implications for study design. Genomics 2002; 79:104-113.
28. Liu W, Mei R, Di X, Ryder TB, Hubbell E, Dee S, Webster TA, Harrington CA, Ho M, Baid J, Smeekens SP. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002; 18:1593-1599.
29. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18:39-51.
30. Nikawa T, Ishidoh K, Hirasaka K, Ishihara I, Ikemoto M, Kano M, Kominami E, Nonaka I, Ogawa T, Adams GR, Baldwin KM, Yasui N, Kishi K, Takeda S. Skeletal muscle gene expression in space-flown rats. FASEB J 2004; 18:522-524.
31. Furuyama T, Kitayama K, Yamashita H, Mori N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 2003; 375:365-371.
32. Machida S, Spangenburg EE, Booth FW. Forkhead transcription factor FoxO1 transduces insulin-like growth factor's signal to p27Kip1 in primary skeletal muscle satellite cells. J Cell Physiol 2003; 196:523-531.
33. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419:316-321.
34. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10:1201-1204.
35. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
36. Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, van Hees HW, Dekhuijzen PN. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:997-1002.
37. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, LeBlanc P, Maltais F. Muscle atrophy and hypertrophy signalling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 200605-2704OC.
38. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3:1009-1013.
39. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, Nishino I, Ezaki O. Skeletal muscle foxo1 (fkhr) transgenic mice have less skeletal muscle mass, down-regulated type i (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279:41114-41123.
40. Whittom F, Jobin J, Simard PM, Leblanc P, Simard C, Bernard S, Belleau R, Maltais F. Histochemical and morphological characteristics of the vastus lateralis muscle in COPD patients. Comparison with normal subjects and effects of exercise training. Med Sci Sports Exerc 1998; 30:1467-1474.
41. Maltais F, Leblanc P, Whittom F, Simard C, Marquis K, Belanger M, Breton MJ, Jobin J. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000; 55:848-853.
42. Saey D, Debigare R, Leblanc P, Mador MJ, Cote CH, Jobin J, Maltais F. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with COPD. Am J Respir Crit Care Med 2003, 168:425-430.
43. Mador MJ, Kufel TJ, Pineda L. Quadriceps fatigue following cycle exercise in patients with COPD. Am J Respir Crit Care Med 2000; 161:447-453.
44. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Neurosci Lett 2003; 342:13-16.
45. Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, Brent GA, Hershman JM. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2003; 88:4990-4996.
46. Cuomo R, Dattilo M, Pumpo R, Capuano G, Boselli L, Budillon G. Nicotinamide methylation in patients with cirrhosis. J Hepatol 1994; 20:138-142.
47. Parsons RB, Smith ML, Williams AC, Waring RH, Ramsden DB. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. J Neuropathol Exp Neurol 2002; 61:111-124.
48. Zerega B, Pagano A, Pianezzi A, Ulivi V, Camardella L, Cancedda R, Cancedda FD. Expression of serum amyloid A in chondrocytes and myoblasts differentiation and inflammation: possible role in cholesterol homeostasis. Matrix Biol 2004; 23:35-46.
49. Staiger H, Kausch C, Guirguis A, Weisser M, Maerker E, Stumvoll M, Lammers R, Machicao F, Haring HU. Induction of adiponectin gene expression in human myotubes by an adiponectin-containing HEK293 cell culture supernatant. Diabetologia 2003; 46:956-960.
50. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation inmuscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98:2005-2010.
51. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300.
52. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59:483-487.
53. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58:752-756.
54. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210-215.
55. Debigare R, Marquis K, Cote CH, Tremblay RR, Michaud A, Leblanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-89.
56. Schols AMWJ, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51: 819-824.
57. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1414-1418.
58. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150:1453-1455.
59. Jones SW, Hill RJ, Krasney PA, O'Conner B, Peirce N, Greenhaff PL. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB J 2004; 18:1025-1027.